What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Melanoma, Internal medicine, Surgery, Vemurafenib and Oncology.
His Melanoma research is multidisciplinary, incorporating perspectives in V600E, Ipilimumab and Metastasis.
His study focuses on the intersection of Metastasis and fields such as Immunology with connections in the field of Haematopoiesis and Microvesicles.
His study brings together the fields of Gastroenterology and Internal medicine.
In the subject of general Surgery, his work in Clinical endpoint is often linked to Stage IIIC, thereby combining diverse domains of study.
His Oncology research incorporates elements of Median survival, Randomization and Pathology.
His most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Inhibition of mutated, activated BRAF in metastatic melanoma. (2901 citations)
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET (2209 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Melanoma, Internal medicine, Oncology, Cancer research and Immunology.
His primary area of study in Melanoma is in the field of Vemurafenib.
His Vemurafenib study integrates concerns from other disciplines, such as Dermatology, V600E and Overall survival.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery.
Paul B. Chapman has included themes like Metastatic melanoma, Advanced melanoma, Clinical trial, Dabrafenib and Disease in his Oncology study.
His Cancer research research is multidisciplinary, incorporating perspectives in Mutation, MEK inhibitor, Kinase, MAPK/ERK pathway and Neuroblastoma RAS viral oncogene homolog.
He most often published in these fields:
- Melanoma (65.12%)
- Internal medicine (58.36%)
- Oncology (42.35%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (58.36%)
- Oncology (42.35%)
- Melanoma (65.12%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Melanoma, Ipilimumab and Nivolumab.
His studies link Surgery with Internal medicine.
His Oncology research includes themes of Cancer treatment, Cancer, Advanced melanoma, Clinical trial and Vemurafenib.
The concepts of his Vemurafenib study are interwoven with issues in Clinical endpoint and Survival analysis.
His Melanoma study contributes to a more complete understanding of Cancer research.
His studies examine the connections between Cancer research and genetics, as well as such issues in Neuroblastoma RAS viral oncogene homolog, with regards to Kinase.
Between 2015 and 2021, his most popular works were:
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis (207 citations)
- Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study (95 citations)
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT) (90 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Paul B. Chapman mostly deals with Internal medicine, Melanoma, Oncology, Ipilimumab and In patient.
His Hazard ratio, Pembrolizumab, Cohort and Adverse effect study in the realm of Internal medicine connects with subjects such as MEDLINE.
His Hazard ratio research is multidisciplinary, incorporating elements of Vemurafenib and Dacarbazine.
In his study, he carries out multidisciplinary Melanoma and Erdheim–Chester disease research.
His Oncology research integrates issues from Trametinib, Proportional hazards model and Retrospective cohort study.
His research investigates the connection with Ipilimumab and areas like Nivolumab which intersect with concerns in Common Terminology Criteria for Adverse Events, Clinical trial and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
